Journal of Clinical Endocrinology & Metabolism, Vol 78, 98-102, Copyright © 1994 by Endocrine Society

ARTICLES

Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease

U Feldt-Rasmussen, H Schleusener and P Carayon
Department of Medicine P, University Hospital, Rigshospitalet, Copenhagen, Denmark.

Patients with the hyperthyroidism of Graves' disease (GDH) have a higher risk of relapse after antithyroid drug therapy (ATD) therapy when TSH receptor antibodies (TRAb) are positive, but the practical clinical implication of TRAb as a predictor for relapse is still much debated. This study was undertaken to investigate by meta-analysis the results from the literature on the use of TRAb as predictor of long term (i.e. at least 1 yr) relapse after ATD. Eighteen publications from 1975-1991 fulfilled the criteria of 1) availability of TRAb at the end of ATD treatment, 2) at least 1 yr of follow-up after ATD, 3) data presentation in a form suitable for meta-analysis, and 4) no other thyroid-related therapy during the follow-up period. The 10 prospective studies, 5 of which measured TSH binding inhibiting immunoglobulins (total n = 597) and 5 of which measured thyroid-stimulating antibodies (n = 340), were computed together because no significant differences were found. In contrast, retrospective and prospective studies differed. In the prospective studies, the odds reduction of relapse showed 65% less risk of relapse when TRAb were absent compared to that in TRAb-positive patients (P < 0.00001). The present meta-analysis has, thus, confirmed in a large number of patients (n = 1524) that absence of TRAb is significantly protective against relapse of GDH after ATD treatment. However, 25% of the patients are "misclassified," and the main questions arising from the study are, therefore, the following. 1) Is it worthwhile to use TRAb as predictor of relapse? 2) Should patients with GDH continue ATD until TRAb becomes negative, rather than for a fixed period? The available methods for TRAb do not allow sufficiently high prediction of relapse or remission after ATD for the individual patient.

This article has been cited by other articles:

				F. Kaguelidou, C. Alberti, M. Castanet, M.-A. Guitteny, P. Czernichow, J. Leger, and for the French Childhood Graves' Disease Study Gro Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3817 - 3826. [Abstract] [Full Text] [PDF]

				A Boschi, C. Daumerie, M Spiritus, C Beguin, M Senou, D Yuksel, M Duplicy, S Costagliola, M Ludgate, and M C Many Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy Br J Ophthalmol, June 1, 2005; 89(6): 724 - 729. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]

				D. D Streetman and U. Khanderia Diagnosis and Treatment of Graves Disease Ann. Pharmacother., July 1, 2003; 37(7): 1100 - 1109. [Abstract] [Full Text] [PDF]

				T. Y. Kim, Y. J. Park, D. J. Park, H.-K. Chung, W. B. Kim, L. D. Kohn, and B. Y. Cho Epitope Heterogeneity of Thyroid-Stimulating Antibodies Predicts Long-Term Outcome in Graves' Patients Treated with Antithyroid Drugs J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 117 - 124. [Abstract] [Full Text] [PDF]

				C. Massart and D. Maugendre Importance of the Detection Method for Thyroglobulin Antibodies for the Validity of Thyroglobulin Measurements in Sera from Patients with Graves Disease Clin. Chem., January 1, 2002; 48(1): 102 - 107. [Abstract] [Full Text] [PDF]

				L. J. S. Brokken, J. W. C. Scheenhart, W. M. Wiersinga, and M. F. Prummel Suppression of Serum TSH by Graves' Ig: Evidence for a Functional Pituitary TSH Receptor J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4814 - 4817. [Abstract] [Full Text] [PDF]

				Y. Watanabe, H. Tada, Y. Hidaka, T. Takano, K. Takeoka, S. Fukata, K. Kuma, and N. Amino Polyethylene Glycol Increases the Detection of Anti-Thyrotropin Receptor Antibodies by a Radioreceptor Assay Clin. Chem., March 1, 1999; 45(3): 407 - 409. [Full Text] [PDF]

				S. Costagliola, N. G. Morgenthaler, R. Hoermann, K. Badenhoop, J. Struck, D. Freitag, S. Poertl, W. Weglöhner, J. M. Hollidt, B. Quadbeck, et al. Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves' Disease J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 90 - 97. [Abstract] [Full Text]

				T. F. Davies Thyroid-Stimulating Antibodies Predict Hyperthyroidisma J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3777 - 3781. [Full Text]

				A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, and A. SanmartI Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism? J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2410 - 2413. [Abstract] [Full Text] [PDF]

				N. S. Glaser and D. M. Styne Predictors of Early Remission of Hyperthyroidism in Children J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1719 - 1726. [Abstract] [Full Text] [PDF]